What is Takeda Pharmaceutical Co Enterprise Value?
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Takeda Pharmaceutical Co's Enterprise Value is €64,472 Mil.
Takeda Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €2,111 Mil. Therefore, Takeda Pharmaceutical Co's EV-to-EBIT ratio for today is 30.55.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Takeda Pharmaceutical Co's Enterprise Value
For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Takeda Pharmaceutical Co's Enterprise Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Takeda Pharmaceutical Co's Enterprise Value falls into.
Takeda Pharmaceutical Co Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Takeda Pharmaceutical Co's Enterprise Value for the fiscal year that ended in Mar. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Takeda Pharmaceutical Co (WBO:TKD) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Takeda Pharmaceutical Co's EV-to-EBIT for today is
Takeda Pharmaceutical Co's current Enterprise Value is €64,472 Mil.
Takeda Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €2,111 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Takeda Pharmaceutical Co's EV-to-EBITDA for today is:
Takeda Pharmaceutical Co's current Enterprise Value is €64,472 Mil.
Takeda Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €7,072 Mil.
Takeda Pharmaceutical Co's current Enterprise Value is €64,472 Mil.
Takeda Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €27,281 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Takeda Pharmaceutical Co Enterprise Value Related Terms
Thank you for viewing the detailed overview of Takeda Pharmaceutical Co's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Takeda Pharmaceutical Co (WBO:TKD) Business Description
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4 trillion in fiscal 2022. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
WBO:TKD has been successfully added to your 